These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697 [TBL] [Abstract][Full Text] [Related]
28. New and emerging treatments for advanced prostate cancer. George DJ; Kantoff PW; Lin DW Clin Adv Hematol Oncol; 2011 Jun; 9(6 Suppl 12):1-15. PubMed ID: 22361744 [TBL] [Abstract][Full Text] [Related]
29. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). Sonpavde G; Wang CG; Galsky MD; Oh WK; Armstrong AJ BJU Int; 2015 Jul; 116(1):17-29. PubMed ID: 25046451 [TBL] [Abstract][Full Text] [Related]
30. Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer. Van Poppel H Can J Urol; 2005 Feb; 12 Suppl 1():81-5. PubMed ID: 15780173 [TBL] [Abstract][Full Text] [Related]
32. Management of metastatic prostate cancer: the crucial role of geriatric assessment. Droz JP; Chaladaj A BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689 [TBL] [Abstract][Full Text] [Related]
33. Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. George DJ; Kantoff PW; Lin DW Clin Adv Hematol Oncol; 2011 Jun; 9(6):1-11; discussion 11-5. PubMed ID: 21941983 [TBL] [Abstract][Full Text] [Related]
34. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985 [TBL] [Abstract][Full Text] [Related]